Abstract
Purpose
Observational studies have shown that among patients on hemodialysis, hyperkalemia is strongly associated with excess risk for cardiovascular-related hospitalizations and sudden cardiac death. However, the actual burden of hyperkalemia, the rates of its recurrence and seasonality in its variation still remain unclear.
Methods
Between June 2020 and May 2021, 1786 mid-week pre-dialysis serum potassium (sK) measurements were retrospectively recorded from 149 patients receiving thrice-weekly hemodialysis in a single-center in Thessaloniki, Greece. The prevalence, recurrence and seasonal variation of hyperkalemia were assessed using three pre-specified sK thresholds (≥ 5.1, ≥ 5.5 and ≥ 6.0 mmol/L).
Results
At baseline, 60.4%, 42.2% and 13.4% of patients had sK levels ≥ 5.1, ≥ 5.5 and ≥ 6.0 mmol/L, respectively. At any time-point during follow-up, 85.2%, 69.8% and 38.9% of patients experienced at least one hyperkalemic event ≥ 5.1, ≥ 5.5 and ≥ 6.0 mmol/L, respectively. Of the 104 patients experiencing an initial sK elevation ≥ 5.5 mmol/L, hyperkalemia at the same threshold reoccurred in 60.6% at month 1, in 47.1% at month 2 and in 46.1% at month 3 of follow-up. Seasonal variation was also observed, with the prevalence of hyperkalemia to be significantly higher in summer. Shorter delivered hemodialysis < 4 h/session (OR: 2.568; 95% CI 1.045–6.313) and the use of a high dialysate K concentration (OR: 14.646; 95% CI 2.727–78.647) were the 2 factors that were independently associated with hyperkalemia.
Conclusion
The present study shows that among hemodialysis patients, the rates of hyperkalemia prevalence and recurrence are very high, reflecting the large unmet need to identify more effective potassium-lowering therapeutic interventions in this high-risk population.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Samanta R, Chan C, Chauhan VS (2019) Arrhythmias and sudden cardiac death in end stage renal disease: epidemiology, risk factors, and management. Can J Cardiol 35:1228–1240
Iseki K, Uehara H, Nishime K et al (1996) Impact of the initial levels of laboratory variables on survival in chronic dialysis patients. Am J Kidney Dis 28:541–548
Kovesdy CP, Regidor DL, Mehrotra R et al (2007) Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol 2:999–1007
Pun PH, Lehrich RW, Honeycutt EF, Herzog CA, Middleton JP (2011) Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int 79:218–227
Georgianos PI, Sarafidis PA, Sinha AD, Agarwal R (2015) Adverse effects of conventional thrice-weekly hemodialysis: is it time to avoid 3-day interdialytic intervals? Am J Nephrol 41:400–408
Krishnasamy R, Badve SV, Hawley CM et al (2013) Daily variation in death in patients treated by long-term dialysis: comparison of in-center hemodialysis to peritoneal and home hemodialysis. Am J Kidney Dis 61:96–103
Yusuf AA, Hu Y, Singh B, Menoyo JA, Wetmore JB (2016) Serum potassium levels and mortality in hemodialysis patients: a retrospective cohort study. Am J Nephrol 44:179–186
Karaboyas A, Robinson BM, James G et al (2021) Hyperkalemia excursions are associated with an increased risk of mortality and hospitalizations in hemodialysis patients. Clin Kidney J 14:1760–1769
Khedr E, Abdelwhab S, El-Sharkawy M, Ali M, El S (2009) Prevalence of hyperkalemia among hemodialysis patients in Egypt. Ren Fail 31:891–898
Rossignol P, Lamiral Z, Frimat L et al (2017) Hyperkalaemia prevalence, recurrence and management in chronic haemodialysis: a prospective multicentre French regional registry 2-year survey. Nephrol Dial Transplant 32:2112–2118
Cheung AK, Yan G, Greene T et al (2002) Seasonal variations in clinical and laboratory variables among chronic hemodialysis patients. J Am Soc Nephrol 13:2345–2352
Usvyat LA, Carter M, Thijssen S et al (2012) Seasonal variations in mortality, clinical, and laboratory parameters in hemodialysis patients: a 5-year cohort study. Clin J Am Soc Nephrol 7:108–115
Fishbane S, Charytan DM, Chertow GM et al (2021) Consensus-based recommendations for the management of hyperkalemia in the hemodialysis setting. J Ren Nutr. https://doi.org/10.1053/j.jrn.2021.06.003 (OnLine Ahead Of Print)
Sinha AD, Agarwal R (2013) Chronic renal disease progression: treatment strategies and potassium intake. Semin Nephrol 33:290–299
Ramos CI, Gonzalez-Ortiz A, Espinosa-Cuevas A, Avesani CM, Carrero JJ, Cuppari L (2020) Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease? Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfaa232 (OnLine Ahead Of Print)
Gonzalez-Ortiz A, Xu H, Ramos-Acevedo S et al (2021) Nutritional status, hyperkalaemia and attainment of energy/protein intake targets in haemodialysis patients following plant-based diets: a longitudinal cohort study. Nephrol Dial Transplant 36:681–688
Pun PH (2018) Dialysate potassium concentration: Should mass balance trump electrophysiology? Semin Dial 31:569–575
Karaboyas A, Zee J, Brunelli SM et al (2017) Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 69:266–277
Jadoul M, Karaboyas A, Goodkin DA et al (2014) Potassium-binding resins: associations with serum chemistries and interdialytic weight gain in hemodialysis patients. Am J Nephrol 39:252–259
Noel JA, Bota SE, Petrcich W et al (2019) Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA Intern Med 179:1025–1033
Georgianos PI, Agarwal R (2018) Revisiting RAAS blockade in CKD with newer potassium-binding drugs. Kidney Int 93:325–334
Bushinsky DA, Rossignol P, Spiegel DM (2016) Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis. Am J Nephrol 44:404–410
Fishbane S, Ford M, Fukagawa M et al (2019) A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia. J Am Soc Nephrol 30:1723–1733
Funding
This study was not supported by any source and represents an original effort of the authors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflict of interest relevant to this work.
Statement of human and animal rights
All procedures performed in the study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments.
Informed consent
Not applicable, given the retrospective nature of the study using medical records.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tsiagka, D., Georgianos, P.I., Pikilidou, M.I. et al. Prevalence, recurrence and seasonal variation of hyperkalemia among patients on hemodialysis. Int Urol Nephrol 54, 2327–2334 (2022). https://doi.org/10.1007/s11255-022-03142-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-022-03142-3